Additionally, we examined whether the IFN score, especially the type I IFN score, correlates with disease activity in patients with anti-MDA5+ DM, along with its association with laboratory findings and ability to predict 3-month mortality. This evidence concerns the gene IFIH1 and dermatomyositis.